<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325298</url>
  </required_header>
  <id_info>
    <org_study_id>IND 109752</org_study_id>
    <nct_id>NCT01325298</nct_id>
  </id_info>
  <brief_title>UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia</brief_title>
  <official_title>UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Center for Corrective Eye Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Center for Corrective Eye Surgery</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate two different ultraviolet (UV) dosing
      regimens for corneal collagen cross linking to slow the progressive changes in corneal
      curvature in eyes with progressive keratoconus or post-refractive surgery ectasia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in corneal curvature</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by maximum keratometry (Kmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>corrected distance acuity</measure>
    <time_frame>6 months</time_frame>
    <description>best spectacle corrected distance acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>corneal endothelial cell count</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pachymetry</measure>
    <time_frame>6 months</time_frame>
    <description>Minimal corneal thickness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Keratoconus</condition>
  <condition>Ectasia</condition>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>20 Minute UV-X Light Treatment Duration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 Minute UV-X Light Treatment Duration
Note: &quot;UV-X&quot; is the trademark of Peschke GmbH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 Minute UV-X Light Treatment Duration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 Minute UV-X Light Treatment Duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UV-X Light</intervention_name>
    <description>UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%</description>
    <arm_group_label>20 Minute UV-X Light Treatment Duration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.</description>
    <arm_group_label>20 Minute UV-X Light Treatment Duration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UV-X Light</intervention_name>
    <description>UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%</description>
    <arm_group_label>30 Minute UV-X Light Treatment Duration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.</description>
    <arm_group_label>30 Minute UV-X Light Treatment Duration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Age 14 years or older for keratoconus subjects since disease often begins at puberty,
        and 18 years or older for post-refractive surgery keratectasia and post-transplant patients

        ii. Signed, dated, written informed consent

        iii. Having documented ectasia on topography or tomography after previous refractive
        surgery OR progressive keratoconus defined as one or more of the following changes over a
        period of 24 months or less before randomization:

          -  An increase of at least 1.0 diopter in the steepest keratometry value (or sim K), or

          -  an increase of at least 1.0 diopter in regular astigmatism evaluated by subjective
             manifest refraction, or

          -  a myopic shift (decrease in the spherical equivalent) of at least 0.5 diopters on
             subjective refraction, or

          -  documented decrease in visual acuity associated with irregular astigmatism and
             topographic features of ectasia

        iv. Have minimal preoperative corneal thickness of 375 microns or more, as measured in the
        office with epithelium not yet removed

        v. For subjects with non-post refractive surgery keratoconus diagnosis only:

          -  14 years or older to 55 years of age,

          -  axial topography consistent with keratoconus such as presence of abnormal central or
             paracentral steepening on the corneal topography map, or presence of one or more slit
             lamp findings associated with keratoconus, such as

               -  Fleischer ring

               -  Vogt striae

               -  Corneal thinning

               -  Corneal scarring

        vi. For contact lens wearers only:

        Removal of contact lenses for the required period of time prior to final screening
        refraction:

          -  Contact lens minimum discontinuation time two weeks for soft, extended wear, soft
             toric, and rigid gas permeable lenses

        vii. For patients with post-refractive surgery keratectasia:

          -  History of excimer laser refractive surgery with increasing refractive astigmatism and
             corneal topographic or keratometric astigmatism of 0.5 or more, or a history of
             decreasing best spectacle corrected visual acuity associated with the presence of
             topography suggestive of keratoconus or pellucid marginal degeneration or abnormal
             higher order aberrations (especially coma) on the aberration mapping of the eye.

        viii. For patients with corneal transplants:

          -  History of corneal transplant for keratoconus with documented increasing refractive
             astigmatism and corresponding topographic irregularity occurring at least one year
             after corneal transplantation, not attributable to transplant suture removal and
             occurring during the most recent two years.

        Exclusion Criteria:

        i. Patients with excessively thin corneas. (Intraoperative minimal corneal thickness in the
        swollen state with the epithelium removed must exceed 400 microns)

        ii. Keratometric readings greater than 62D

        iii. No evidence of keratoconus/keratectasia progression over the prior three years

        iv. Age less than 55 years but under

          -  14 years for keratoconus patients

          -  18 years for post-refractive surgery keratectasia and post-transplant patients

             v. Previous ocular condition in the eye(s) to be treated that might, in the
             investigator's opinion, predispose to complications (such as history herpes simplex
             keratitis, corneal melt, perforated corneal ulcer, descemetocele, prior corneal damage
             from chemical injury, herpes zoster keratitis, nystagmus, corneal scarring that
             significantly impairs vision, pre-existing glaucoma, glaucoma suspect, Goldmann
             applanation pressure exceeding 23 mm Hg, cataract, history of uveitis, active ocular
             disease that might lead to infection, corneal endothelial cell count below 1800 cells
             per square millimeter)

        vi. Patients with a systemic condition that, in the investigator's opinion, might
        predispose to complications (such as Down syndrome, autoimmune disease, pregnancy or
        nursing at the time of initial treatment, history of alcohol abuse, being
        immunocompromised, allergy to riboflavin or other study medications)

        vii. Patients who are unwilling or unable to comply with the study regimen and doctor's
        advice

        viii. Patients unwilling to discontinue wear of rigid contact lenses in the eye to be
        operated on for at least one month before baseline examination, and for the first six
        months postâˆ’operatively

        ix. Patient unwilling to discontinue contact lenses prior to baseline exam: one week for
        soft lenses, two weeks for rigid or soft toric lenses

        x. Pregnancy at the time of proposed crosslinking

        xi. Known hypersensitivity to riboflavin

        xii. Central corneal endothelial cell count below 1400 cells per square millimeter.

        xiii. Presence of significant central corneal stromal scar

        xiv. History of delayed wound healing

        xv. Immunocompromised patient

        xvi. History of connective tissue disease (such as systemic lupus erythematosus, rheumatoid
        arthritis)

        xvii. History of glaucoma, a Goldmann applanation pressure measured in keratoconus
        evaluation of above 24, or glaucoma suspect, xviii. Significant existing cataract

        xix. Macular degeneration or confluent drusen of Bruchs membrane

        xx. Evidence of past or present herpes simplex of the cornea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L Epstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Center for Corrective Eye Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charisse Haas</last_name>
    <phone>815-363-2020</phone>
    <email>chaas@mhsjvl.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark A Gurgos, COT</last_name>
    <phone>815-363-2020</phone>
    <email>mgurgos@mhsjvl.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mercy Center for Corrective Eye Surgery</name>
      <address>
        <city>McHenry</city>
        <state>Illinois</state>
        <zip>60050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Gurgos, COT</last_name>
      <phone>815-363-2020</phone>
      <email>mgurgos@mhsjvl.org</email>
    </contact>
    <contact_backup>
      <last_name>Robert L Epstein, MD</last_name>
      <phone>815-363-2020</phone>
      <email>rlepstein@aol.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert L Epstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ICanSee.com</url>
    <description>Educational material in website of Mercy Center for Corrective Eye Surgery</description>
  </link>
  <results_reference>
    <citation>Caporossi A, Mazzotta C, Baiocchi S, Caporossi T. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. Am J Ophthalmol. 2010 Apr;149(4):585-93. doi: 10.1016/j.ajo.2009.10.021. Epub 2010 Feb 6.</citation>
    <PMID>20138607</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldich Y, Marcovich AL, Barkana Y, Avni I, Zadok D. Safety of corneal collagen cross-linking with UV-A and riboflavin in progressive keratoconus. Cornea. 2010 Apr;29(4):409-11. doi: 10.1097/ICO.0b013e3181bd9f8c.</citation>
    <PMID>20164744</PMID>
  </results_reference>
  <results_reference>
    <citation>Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008 Sep;24(7):S720-5.</citation>
    <PMID>18811118</PMID>
  </results_reference>
  <results_reference>
    <citation>Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801. doi: 10.1016/j.jcrs.2007.12.039.</citation>
    <PMID>18471635</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazzotta C, Traversi C, Baiocchi S, Sergio P, Caporossi T, Caporossi A. Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. Eur J Ophthalmol. 2006 Jul-Aug;16(4):530-5.</citation>
    <PMID>16952090</PMID>
  </results_reference>
  <results_reference>
    <citation>Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006 May;32(5):837-45.</citation>
    <PMID>16765803</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>March 28, 2011</last_update_submitted>
  <last_update_submitted_qc>March 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Robert L. Epstein, MD</name_title>
    <organization>Mercy Center for Corrective Eye Surgery</organization>
  </responsible_party>
  <keyword>Keratoconus</keyword>
  <keyword>Ectasia</keyword>
  <keyword>cross linking</keyword>
  <keyword>collagen cross linking</keyword>
  <keyword>corneal crosslinking</keyword>
  <keyword>corneal diseases</keyword>
  <keyword>eye diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

